294 related articles for article (PubMed ID: 23834553)
41. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Chen CY; Lin TY; Wang CC; Shuai HA
Psychiatry Clin Neurosci; 2011 Feb; 65(1):95-7. PubMed ID: 21265942
[TBL] [Abstract][Full Text] [Related]
42. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
[TBL] [Abstract][Full Text] [Related]
43. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Yen YC; Lung FW; Chong MY
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
[TBL] [Abstract][Full Text] [Related]
44. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
Coronas R; Cobo J; Giménez-Palop O; Ortega E; Márquez M
Curr Drug Saf; 2012 Apr; 7(2):92-8. PubMed ID: 22873493
[TBL] [Abstract][Full Text] [Related]
45. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.
Webster J; Piscitelli G; Polli A; D'Alberton A; Falsetti L; Ferrari C; Fioretti P; Giordano G; L'Hermite M; Ciccarelli E
Clin Endocrinol (Oxf); 1992 Dec; 37(6):534-41. PubMed ID: 1286524
[TBL] [Abstract][Full Text] [Related]
46. Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.
Charan A; Shewade DG; Rajkumar RP; Chandrasekaran A
Psychiatry Res; 2016 Jun; 240():209-213. PubMed ID: 27111215
[TBL] [Abstract][Full Text] [Related]
47. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
[TBL] [Abstract][Full Text] [Related]
48. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
Ciccarelli E; Grottoli S; Razzore P; Gaia D; Bertagna A; Cirillo S; Cammarota T; Camanni M; Camanni F
J Endocrinol Invest; 1997 Oct; 20(9):547-51. PubMed ID: 9413809
[TBL] [Abstract][Full Text] [Related]
49. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Gillam MP; Middler S; Freed DJ; Molitch ME
J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
[TBL] [Abstract][Full Text] [Related]
50. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients.
De Luis DA; Becerra A; Lahera M; Botella JI; Valero ; Varela C
J Endocrinol Invest; 2000; 23(7):428-34. PubMed ID: 11005266
[TBL] [Abstract][Full Text] [Related]
51. Effect of cabergoline on metabolism in prolactinomas.
Auriemma RS; Granieri L; Galdiero M; Simeoli C; Perone Y; Vitale P; Pivonello C; Negri M; Mannarino T; Giordano C; Gasperi M; Colao A; Pivonello R
Neuroendocrinology; 2013; 98(4):299-310. PubMed ID: 24355865
[TBL] [Abstract][Full Text] [Related]
52. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
Tschoner A; Engl J; Rettenbacher MA; Kaser S; Ott HW; Fleischhacker WW; Patsch JR; Ebenbichler CF
J Clin Psychiatry; 2009 Feb; 70(2):293-4. PubMed ID: 19265646
[No Abstract] [Full Text] [Related]
53. [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Pascal-Vigneron V; Weryha G; Bosc M; Leclere J
Presse Med; 1995 Apr; 24(16):753-7. PubMed ID: 7784413
[TBL] [Abstract][Full Text] [Related]
54. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.
Muratori M; Arosio M; Gambino G; Romano C; Biella O; Faglia G
J Endocrinol Invest; 1997 Oct; 20(9):537-46. PubMed ID: 9413808
[TBL] [Abstract][Full Text] [Related]
55. Dopamine partial agonism in antipsychotic-induced sexual dysfunction.
Mesa N; de la Oliva J; Bagney A; Jimenez-Arriero MA; Rodriguez-Jimenez R
Actas Esp Psiquiatr; 2013; 41(2):130-2. PubMed ID: 23592073
[TBL] [Abstract][Full Text] [Related]
56. Cabergoline.
Colao A; Lombardi G; Annunziato L
Expert Opin Pharmacother; 2000 Mar; 1(3):555-74. PubMed ID: 11249538
[TBL] [Abstract][Full Text] [Related]
57. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
58. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone.
Markianos M; Hatzimanolis J; Lykouras L
Psychiatry Res; 1999 Dec; 89(2):115-22. PubMed ID: 10646830
[TBL] [Abstract][Full Text] [Related]
59. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
[TBL] [Abstract][Full Text] [Related]
60. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.
Gibson CD; Karmally W; McMahon DJ; Wardlaw SL; Korner J
Diabetes Obes Metab; 2012 Apr; 14(4):335-40. PubMed ID: 22074059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
